S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Recent Reports Are A Wake-Up Call For Investors (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
An Unusual Way to Invest in Gold (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Basilea Pharmaceutica Stock Price, News & Analysis (OTCMKTS:BPMUF)

$41.00
0.00 (0.00%)
(As of 12/7/2023 ET)
Compare
Today's Range
$41.00
$41.00
50-Day Range
$41.00
$50.00
52-Week Range
$41.00
$41.00
Volume
N/A
Average Volume
N/A
Market Capitalization
$485.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BPMUF stock logo

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

BPMUF Stock Price History

BPMUF Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Basilea Pharma Submits NDA For Antibiotic Ceftobiprole
Basilea Pharmaceutica Posts FY Profit
Basilea Pharma Expects Net Profit In FY22
Basilea announces repayment of 2022 convertible bonds
See More Headlines
Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BPMUF
CIK
N/A
Employees
143
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$154.86 million
Cash Flow
$1.17 per share
Book Value
($1.83) per share

Miscellaneous

Free Float
N/A
Market Cap
$485.89 million
Optionable
Not Optionable
Beta
0.82

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. David Veitch (Age 58)
    Chief Executive Officer
    Comp: $1.35M
  • Mr. Adesh Kaul (Age 49)
    Chief Financial Officer
  • Dr. Gerrit Hauck Ph.D. (Age 59)
    Chief Technology Officer
  • Dr. Laurenz Kellenberger Ph.D. (Age 56)
    Chief Scientific Officer
  • Dr. Marc Engelhardt M.D. (Age 59)
    Chief Medical Officer
  • Dr. Peer Nils Schroder
    Head of Corporate Communications & Investor Relations
  • Mr. Damian Heller (Age 57)
    General Counsel & Corporate Secretary
  • Ms. Ursula Eberhardt (Age 61)
    Head of Global Human Resources
  • Mr. Mark Jones (Age 55)
    Head of Project Management & Preclinical Development
  • Mr. Peter Bielmeier Ph.D. (Age 56)
    Head of Global Quality Management














BPMUF Stock Analysis - Frequently Asked Questions

How have BPMUF shares performed in 2023?

Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of the year. Since then, BPMUF stock has decreased by 21.2% and is now trading at $41.00.
View the best growth stocks for 2023 here
.

Are investors shorting Basilea Pharmaceutica?

Basilea Pharmaceutica saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 258,800 shares, a decrease of 9.0% from the October 15th total of 284,400 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 2,588.0 days.
View Basilea Pharmaceutica's Short Interest
.

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Basilea Pharmaceutica have any subsidiaries?
The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.
Read More
This page (OTCMKTS:BPMUF) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -